CD4 and myeloid sarcoma: In addition to the autoreactivity of the CD4+ and CD8+ T-cells, effector T-cells isolated from MS patients demonstrate resistance to the suppressive functions of regulatory T-cells (Kaskow and Baecher-Allan, 2018).